The DOI matches its Crossref record; 53 of the 54 references it cites were found in a registry or an index.
Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines
Open accessAbstract
The Adult Treatment Panel III (ATP III) of the National Cholesterol Education Program issued an evidence-based set of guidelines on cholesterol management in 2001. Since the publication of ATP III, 5 major clinical trials of statin therapy with clinical end points have been published. These trials addressed issues that were not examined in previous clinical trials of cholesterol-lowering therapy. The present document reviews the results of these recent trials and assesses their implications for cholesterol management. Therapeutic lifestyle changes (TLC) remain an essential modality in clinical management. The trials confirm the benefit of cholesterol-lowering therapy in high-risk patients and support the ATP III treatment goal of low-density lipoprotein cholesterol (LDL-C) <100 mg/dL. They support the inclusion of patients with diabetes in the high-risk category and confirm the benefits of LDL-lowering therapy in these patients. They further confirm that older persons benefit from therapeutic lowering of LDL-C. The major recommendations for modifications to footnote the ATP III treatment algorithm are the following. In high-risk persons, the recommended LDL-C goal is <100 mg/dL, but when risk is very high, an LDL-C goal of <70 mg/dL is a therapeutic option, ie, a reasonable clinical strategy, on the basis of available clinical trial evidence. This therapeutic option extends also to patients at very high risk who have a baseline LDL-C <100 mg/dL. Moreover, when a high-risk patient has high triglycerides or low high-density lipoprotein cholesterol (HDL-C), consideration can be given to combining a fibrate or nicotinic acid with an LDL-lowering drug. For moderately high-risk persons (2+ risk factors and 10-year risk 10% to 20%), the recommended LDL-C goal is <130 mg/dL, but an LDL-C goal <100 mg/dL is a therapeutic option on the basis of recent trial evidence. The latter option extends also to moderately high-risk persons with a baseline LDL-C of 100 to 129 mg/dL. When LDL-lowering drug therapy is employed in high-risk or moderately high-risk persons, it is advised that intensity of therapy be sufficient to achieve at least a 30% to 40% reduction in LDL-C levels. Moreover, any person at high risk or moderately high risk who has lifestyle-related risk factors (eg, obesity, physical inactivity, elevated triglycerides, low HDL-C, or metabolic syndrome) is a candidate for TLC to modify these risk factors regardless of LDL-C level. Finally, for people in lower-risk categories, recent clinical trials do not modify the goals and cutpoints of therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The use of combination fibrate–statin therapy in such patients is consistent with current guidelines that recommend treatment for patients with hypertriglyceridemia and low HDL cholesterol levels that persist despite statin therapy.25”
From Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus (2010) · cites this paper as [25]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“According to practice guidelines in place at the time of patient enrollment in IMPROVE-IT, treatment of hypercholesterolemia was based on lowering LDL cholesterol to target levels, 20,21 which were set on the basis of a patient's risk of cardiovascular events.”
From Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes (2015) · cites this paper as [20]
In the citing paper
“Statins are currently the most effective agents available for managing dyslipidemia and have been shown to reduce CV events in a wide variety of patient populations [10,25,31].”
In the citing paper
“Statins are currently the most effective agents available for managing dyslipidemia and have been shown to reduce CV events in a wide variety of patient populations [10,25,31].”
In the citing paper
“Assiduous attention to abnormalities other than hyperglycemia that accompany type 2 diabetes, such as hypertension and dyslipidaemia, has been shown to improve microvascular and cardiovascular complications.”
From Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy (2009) · cites this paper as [21]
In the citing paper
“Nevertheless, measurement and treatment of blood lipids, blood pressure, and glucose levels have became the major emphases for cardiovascular risk reduction.”
From Beyond Established and Novel Risk Factors: Lifestyle Risk Factors for Cardiovascular Disease (2008) · cites this paper as [25]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972) · Clinical Chemistry · doi:10.1093/clinchem/18.6.499 · Cited by 32,423
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,944
Self-citationExpert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
Grundy, S. M., Becker, D. M., Clark, L. T., Cooper, R., Denke, M. A., Howard, J. L., Hunninghake, D. B., Illingworth, D. R., Luepker, R. V., McBride, P. E., et al. (2002) · Civil War Book Review · Cited by 12,198
Self-citationOLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
Pearson, T. A., Mensah, G. A., Alexander, R. W., Anderson, J. L., Cannon, R. O., Criqui, M., Fadl, Y. Y., Fortmann, S. P., Hong, Y., Myers, G. L., et al. (2003) · Circulation · doi:10.1161/01.cir.0000052939.59093.45 · Cited by 6,401
Self-citation
Cited by
Sorted by citations
Items 301–400 of 1,060
Atorvastatin Reduces the Risk of Cardiovascular Events in Patients With Carotid Atherosclerosis
Sillesen, H. H., Amarenco, P., Hennerici, M. G., Callahan, A., Goldstein, L. B., Zivin, J. A., Messig, M., & Welch, K. M. A. (2008) · Stroke · doi:10.1161/strokeaha.108.516450 · Cited by 277
Fraker, T. D., & Fihn, S. D. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.08.002 · Cited by 277
Jones, M. L., Martoni, C. J., & Prakash, S. (2012) · European Journal of Clinical Nutrition · doi:10.1038/ejcn.2012.126 · Cited by 277
Statin-related adverse events: A meta-analysis
Silva, M. A., Swanson, A. C., Gandhi, P. J., & Tataronis, G. R. (2006) · Clinical Therapeutics · doi:10.1016/j.clinthera.2006.01.005 · Cited by 275
Anderson, J. L., Adams, C. D., Antman, E. M., Bridges, C. R., Califf, R. M., Casey, D. E., Chavey, W. E., Fesmire, F. M., Hochman, J. S., Levin, T. N., et al. (2013) · Circulation · doi:10.1161/cir.0b013e31828478ac · Cited by 275
Brunzell, J. D. (2007) · New England Journal of Medicine · doi:10.1056/nejmcp070061 · Cited by 268
Aggressive Versus Moderate Lipid-Lowering Therapy in Hypercholesterolemic Postmenopausal Women
Raggi, P., Davidson, M. H., Callister, T. Q., Welty, F. K., Bachmann, G. A., Hecht, H. S., & Rumberger, J. A. (2005) · Circulation · doi:10.1161/circulationaha.104.512681 · Cited by 272
Pol, K., Christensen, R., Bartels, E. M., Raben, A., Tetens, I., & Kristensen, M. (2013) · American Journal of Clinical Nutrition · doi:10.3945/ajcn.113.064659 · Cited by 272
Toth, P. P., Potter, D. M., & Ming, E. E. (2012) · Journal of clinical lipidology · doi:10.1016/j.jacl.2012.05.002 · Cited by 272
The Evolving Future of PCSK9 Inhibitors
Rosenson, R. S., Hegele, R. A., Fazio, S., & Cannon, C. P. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.04.054 · Cited by 264
Davidson, M. H., Maki, K. C., Pearson, T. A., Pasternak, R. C., Deedwania, P. C., McKenney, J. M., Fonarow, G. C., Maron, D. J., Ansell, B. J., Clark, L. T., et al. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.04.019 · Cited by 270
Self-citationDavidson, M. H., Ballantyne, C. M., Jacobson, T. A., Bittner, V. A., Braun, L. T., Brown, A. S., Brown, W. V., Cromwell, W. C., Goldberg, R. B., McKenney, J. M., et al. (2011) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2011.07.005 · Cited by 262
Stone, N. J., Bilek, S., & Rosenbaum, S. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.06.006 · Cited by 272
Self-citationFactores de riesgo cardiovascular. Perspectivas derivadas del Framingham Heart Study
O’Donnell, C. J., & Elosúa, R. (2008) · Revista Española de Cardiología · doi:10.1157/13116658 · Cited by 282
Teramoto, T., Sasaki, J., Ueshima, H., Egusa, G., Kinoshita, M., Shimamoto, K., Daida, H., Biro, S., Hirobe, K., Funahashi, T., et al. (2007) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.14.45 · Cited by 265
Libby, P., Nathan, D. M., Abraham, K., Brunzell, J. D., Fradkin, J. E., Haffner, S. M., Hsueh, W., Rewers, M., Roberts, B. T., Savage, P. J., et al. (2005) · Circulation · doi:10.1161/circulationaha.104.529651 · Cited by 265
Morrone, D., Weintraub, W. S., Toth, P. P., Hanson, M. E., Lowe, R. S., Lin, J., Shah, A. K., & Tershakovec, A. M. (2012) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2012.02.016 · Cited by 263
Acute Aortic Syndromes and Thoracic Aortic Aneurysm
Ramanath, V. S., Oh, J. K., Sundt, T. M., & Eagle, K. A. (2009) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(11)60566-1 · Cited by 265
Cardiovascular Risk Factors. Insights From Framingham Heart Study
O’Donnell, C. J., & Elosúa, R. (2008) · Revista Española de Cardiología (English Edition) · doi:10.1016/s1885-5857(08)60118-8 · Cited by 272
Friedewald, V. E., Kornman, K. S., Beck, J. D., Genco, R. J., Goldfine, A. B., Libby, P., Offenbacher, S., Ridker, P. M., Dyke, T. E. V., & Roberts, W. C. (2009) · Journal of Periodontology · doi:10.1902/jop.2009.097001 · Cited by 273
Brain cholesterol turnover required for geranylgeraniol production and learning in mice
Kotti, T. J., Ramirez, D. M. O., Pfeiffer, B. E., Huber, K. M., & Russell, D. W. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0600316103 · Cited by 270
Low-density lipoprotein size and cardiovascular risk assessment
Rizzo, M., & Berneis, K. K. (2005) · QJM · doi:10.1093/qjmed/hci154 · Cited by 259
KONES, R. J. (2011) · Drug Design Development and Therapy · doi:10.2147/dddt.s14934 · Cited by 266
Dorresteijn, J. A. N., Visseren, F. L. J., Wassink, A. M. J., Gondrie, M. J. A., Steyerberg, E. W., Ridker, P. M., Cook, N. R., van der Graaf, Y., & on behalf of the SMART Study Group (2013) · Heart · doi:10.1136/heartjnl-2013-303640 · Cited by 258
Circulating Markers of Abdominal Aortic Aneurysm Presence and Progression
Golledge, J., Tsao, P. S., Dalman, R. L., & Norman, P. E. (2008) · Circulation · doi:10.1161/circulationaha.108.802074 · Cited by 258
New Fibrate Use and Acute Renal Outcomes in Elderly Adults: A Population-Based Study
Zhao, Y. Y., Weir, M. A., Manno, M., Cordy, P., Gomes, T., Hackam, D. G., Juurlink, D. N., Mamdani, M., Moist, L., Parikh, C. R., et al. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-156-8-201204170-00401 · Cited by 258
Diagnosis and treatment of familial hypercholesterolaemia
Hovingh, G. K., Davidson, M. H., Kastelein, J. J. P., & O’Connor, A. M. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht015 · Cited by 265
Illicit anabolic–androgenic steroid use
Kanayama, G., Hudson, J. I., & Pope, H. G. (2009) · Hormones and Behavior · doi:10.1016/j.yhbeh.2009.09.006 · Cited by 258
Key, T. J., Appleby, P. N., Spencer, E. A., Travis, R. C., Roddam, A., & Allen, N. E. (2009) · American Journal of Clinical Nutrition · doi:10.3945/ajcn.2009.26736l · Cited by 257
Congenital Heart Disease in the Older Adult
Bhatt, A. B., Foster, E., KUEHL, K. S., Alpert, J. S., Brabeck, S., Crumb, S. R., Davidson, W. R., Earing, M. G., Ghoshhajra, B. B., Karamlou, T., et al. (2015) · Circulation · doi:10.1161/cir.0000000000000204 · Cited by 258
Schmermund, A., Achenbach, S. S., Budde, T., Buziashvili, Y. I., Förster, A., Friedrich, G. J., Henein, M., Kerkhoff, G., Knollmann, F. D., Kukharchuk, V. V., et al. (2006) · Circulation · doi:10.1161/circulationaha.105.568147 · Cited by 254
Corn phytochemicals and their health benefits
Siyuan, S., Li, T., & Liu, R. (2018) · Food Science and Human Wellness · doi:10.1016/j.fshw.2018.09.003 · Cited by 254
Effects of High-Dose Modified-Release Nicotinic Acid on Atherosclerosis and Vascular Function
Lee, J. M. S., Robson, M. D., Yu, L.-M., Shirodaria, C. C., Cunnington, C., Kylintireas, I., Digby, J. E., Bannister, T., Handa, A., Wiesmann, F., et al. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.06.036 · Cited by 246
Varbo, A., Benn, M., & Nordestgaard, B. G. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.11.008 · Cited by 251
Deaths Preventable in the U.S. by Improvements in Use of Clinical Preventive Services
Farley, T. A., Dalal, M. R., Mostashari, F., & Frieden, T. R. (2010) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2010.02.016 · Cited by 251
Dyslipidemia, Coronary Artery Calcium, and Incident Atherosclerotic Cardiovascular Disease
Martin, S. S., Blaha, M. J., Blankstein, R., Agatston, A. A., Rivera, J. J., Virani, S. S., Ouyang, P., Jones, S. R., Blumenthal, R. S., Budoff, M. J., et al. (2013) · Circulation · doi:10.1161/circulationaha.113.003625 · Cited by 253
Fuster, V., Halperin, J. L., Hiratzka, L. F., Hunt, S. A., Buller, E., Creager, M. A., Ettinger, S. M., Faxon, D. P., Jacobs, A. K., Adams, C. D., et al. (2007) · Cited by 250
Self-citationBero, L., Oostvogel, F., Bacchetti, P., & Lee, K. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040184 · Cited by 249
2011 ACCF/AHA guideline for coronary artery bypass graft surgery: Executive summary
Hillis, L. D., Smith, P. K., Anderson, J. L., Bittl, J. A., Bridges, C. R., Byrne, J. G., Cigarroa, J. E., DiSesa, V. J., Hiratzka, L. F., Hutter, A. M., et al. (2011) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2011.10.015 · Cited by 251
McDonald, M., Hertz, R. P., Unger, A. N., & Lustik, M. B. (2009) · The Journals of Gerontology Series A · doi:10.1093/gerona/gln016 · Cited by 252
Metabolic stress-induced joint inflammation and osteoarthritis
Courties, A., Gualillo, O., Berenbaum, F., & Sellam, J. (2015) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2015.05.016 · Cited by 249
Pearson, T. A., Palaniappan, L. P., Artinian, N. T., Carnethon, M. R., Criqui, M. H., Daniels, S. R., Fonarow, G. C., Fortmann, S. P., Franklin, B. A., Galloway, J. M., et al. (2013) · Circulation · doi:10.1161/cir.0b013e31828f8a94 · Cited by 261
Pearson, T. A., Denke, M. A., McBride, P. E., Battisti, W. P., Brady, W. E., & Palmisano, J. J. (2005) · Mayo Clinic Proceedings · doi:10.4065/80.5.587 · Cited by 246
Thomas, G. S., Cromwell, W. C., Ali, S., Chin, W., Flaim, J. D., & Davidson, M. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.07.081 · Cited by 245
Effect of Lower Targets for Blood Pressure and LDL Cholesterol on Atherosclerosis in Diabetes
Howard, B. V. (2008) · JAMA · doi:10.1001/jama.299.14.1678 · Cited by 238
Screening for cardiovascular risk in asymptomatic patients
Berger, J. S., Jordan, C. O., Lloyd-Jones, D., & Blumenthal, R. S. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.09.066 · Cited by 238
Alsheikh-Ali, A. A. A., Maddukuri, P. V., Han, H., & Karas, R. H. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.02.073 · Cited by 243
Liu, J., Sempos, C. T., Donahue, R. P., Dorn, J. P., Trevisan, M., & Grundy, S. M. (2005) · Diabetes Care · doi:10.2337/diacare.28.8.1916 · Cited by 237
Self-citationCore Components of Cardiac Rehabilitation/Secondary Prevention Programs: 2007 Update
Balady, G. J., Williams, M. A., Ades, P. A., Bittner, V., Comoss, P. M., Foody, J. A. M., Franklin, B. A., Sanderson, B., & Southard, D. R. (2007) · Journal of Cardiopulmonary Rehabilitation and Prevention · doi:10.1097/01.hcr.0000270696.01635.aa · Cited by 238
Ballantyne, C. M., Abate, N. I., Yuan, Ž., King, T. R., & Palmisano, J. J. (2005) · American Heart Journal · doi:10.1016/j.ahj.2004.11.023 · Cited by 236
Addressing Unmet Basic Resource Needs as Part of Chronic Cardiometabolic Disease Management
Berkowitz, S. A., Hulberg, A. C., Standish, S., Reznor, G., & Atlas, S. J. (2017) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2016.7691 · Cited by 237
Kato, K., Yonetsu, T., Kim, S.-J., Xing, L., Lee, H., McNulty, I., Yeh, R., Sakhuja, R., Zhang, S., Uemura, S., et al. (2012) · Circulation Cardiovascular Imaging · doi:10.1161/circimaging.112.973701 · Cited by 236
Fihn, S. D., Gardin, J. M., Abrams, J., Berra, K., Blankenship, J. C., Dallas, A. P., Douglas, P. S., Foody, J. M., Gerber, T. C., Hinderliter, A. L., et al. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.07.012 · Cited by 242
Self-citationManaging Abnormal Blood Lipids
Fletcher, B. J., Berra, K. A., Ades, P., Braun, L. T., Burke, L. E., Durstine, J. L., Fair, J. M., Fletcher, G. F., Goff, D. C., Hayman, L. L., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.169180 · Cited by 238
Self-citationThe toe-brachial index in the diagnosis of peripheral arterial disease
Høyer, C., Sandermann, J., & Petersen, L. J. (2013) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2013.03.044 · Cited by 249
Lupus Atherosclerosis Prevention Study (LAPS)
Petri, M. A., Kiani, A. N., Post, W. S., Christopher‐Stine, L., & Magder, L. S. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.136762 · Cited by 240
Hollænder, P. L., Ross, A. B., & Kristensen, M. (2015) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.115.109165 · Cited by 233
Ridker, P. M., Morrow, D. A., Rose, L. M., Rifai, N., Cannon, C. P., & Braunwald, E. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.02.080 · Cited by 236
Do Statins Reduce Blood Pressure?
Strazzullo, P., Kerry, S., Barbato, A., Versiero, M., D’Elia, L., & Cappuccio, F. P. (2007) · Hypertension · doi:10.1161/01.hyp.0000259737.43916.42 · Cited by 233
Pandor, A., Ara, R. M., Tumur, I., Wilkinson, A. J., Paisley, S., Duenas, A., Durrington, P. N., & Chilcott, J. (2009) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2008.02062.x · Cited by 228
Hsia, J., MacFadyen, J. G., Monyak, J., & Ridker, P. M. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.09.082 · Cited by 231
Goff, D. C., Gerstein, H. C., Ginsberg, H. N., Cushman, W. C., Margolis, K. L., Byington, R. P., Buse, J. B., Genuth, S., Probstfield, J. L., & Simons-Morton, D. G. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2007.03.002 · Cited by 229
Effects of AMG 145 on Low-Density Lipoprotein Cholesterol Levels
Dias, C. S., Shaywitz, A. J., Wasserman, S. M., Smith, B. P., Gao, B., Stolman, D., Crispino, C., Smirnakis, K. V., Emery, M. G., Colbert, A., et al. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.08.986 · Cited by 234
Genome-Wide Association of Lipid-Lowering Response to Statins in Combined Study Populations
Barber, M., Mangravite, L. M., Hyde, C. L., Chasman, D. I., Smith, J. D., McCarty, C. A., Li, X., Wilke, R. A., Rieder, M. J., Williams, P. T., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009763 · Cited by 231
Vegetarian Dietary Patterns and Cardiovascular Disease
Kahleová, H., Levin, S., & Barnard, N. D. (2018) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2018.05.002 · Cited by 254
A modified formula for calculating low-density lipoprotein cholesterol values
Chen, Y., Zhang, X., Pan, B., Jin, X., Yao, H., Chen, B., Zou, Y., Ge, J., & Chen, H. (2010) · Lipids in Health and Disease · doi:10.1186/1476-511x-9-52 · Cited by 229
High-Density Lipoprotein and Coronary Heart Disease
Natarajan, P., Ray, K. K., & Cannon, C. P. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.01.008 · Cited by 231
Metabolic syndrome and non-alcoholic fatty liver disease
Almeda‐Valdés, P., Ramos, D. C., & Aguilar-Salinas, C. A. (2009) · Annals of Hepatology · doi:10.1016/s1665-2681(19)31822-8 · Cited by 234
The Metabolic Syndrome and Inflammation
Sutherland, J. P., McKinley, B., & Eckel, R. H. (2004) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2004.2.82 · Cited by 243
Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk
Chapman, M. J., Redfern, J. S., McGovern, M. E., & Giral, P. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.01.008 · Cited by 227
Cooney, M. T., Dudina, A., D'Agostino, R., & Graham, I. M. (2010) · Circulation · doi:10.1161/circulationaha.109.852756 · Cited by 222
Crooke, R. M., Graham, M. J., Lemonidis, K. M., Whipple, C. P., Koo, S., & Perera, R. J. (2005) · Journal of Lipid Research · doi:10.1194/jlr.m400492-jlr200 · Cited by 227
Lipid parameters for measuring risk of cardiovascular disease
Arsenault, B. J., Boekholdt, S. M., & Kastelein, J. J. P. (2011) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2010.223 · Cited by 234
Fundamental questions about genes, inactivity, and chronic diseases
Booth, F. W., & Lees, S. J. (2006) · Physiological Genomics · doi:10.1152/physiolgenomics.00174.2006 · Cited by 233
Nuclear Receptors in Lipid Metabolism: Targeting the Heart of Dyslipidemia
Beaven, S. W., & Tontonoz, P. (2006) · Annual Review of Medicine · doi:10.1146/annurev.med.57.121304.131428 · Cited by 230
Kokkinos, P. F., Faselis, C., Myers, J., Panagiotakos, D., & Doumas, M. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61426-3 · Cited by 217
Mann, D., Reynolds, K., Smith, D. A., & Muntner, P. (2008) · Annals of Pharmacotherapy · doi:10.1345/aph.1l181 · Cited by 222
Resistant Starch from High-Amylose Maize Increases Insulin Sensitivity in Overweight and Obese Men
Maki, K. C., Pelkman, C., Finocchiaro, E. T., Kelley, K., Lawless, A. L., Schild, A. L., & Rains, T. M. (2012) · Journal of Nutrition · doi:10.3945/jn.111.152975 · Cited by 229
Applications and Limitations of Mouse Models for Understanding Human Atherosclerosis
von Scheidt, M., Zhao, Y., Kurt, Z., Pan, C., Zeng, L., Yang, X., Schunkert, H., & Lusis, A. J. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.11.001 · Cited by 230
Shepherd, J., Kastelein, J. J. P., Bittner, V., Deedwania, P., Breazna, A., Dobson, S., Wilson, D. J., Zuckerman, A., & Wenger, N. K. (2007) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.04371206 · Cited by 275
Impact of obesity on cardiovascular disease
Zalesin, K. C., Franklin, B. A., Miller, W. M., Peterson, E. D., & McCullough, P. A. (2011) · Medical Clinics of North America · doi:10.1016/j.mcna.2011.06.005 · Cited by 231
Jenkins, D. J. A., Jones, P. J. H., Lamarche, B., Kendall, C. W. C., Faulkner, D., Cermakova, L., Gigleux, I., Ramprasath, V., de Souza, R., Ireland, C., et al. (2011) · JAMA · doi:10.1001/jama.2011.1202 · Cited by 218
Samaha, F. F., McKenney, J., Bloedon, L. T., Sasiela, W. J., & Rader, D. J. (2008) · Nature Clinical Practice Cardiovascular Medicine · doi:10.1038/ncpcardio1250 · Cited by 220
Secondary Prevention of Atherosclerotic Cardiovascular Disease in Older Adults
Fleg, J. L., Forman, D. E., Berra, K. A., Bittner, V., Blumenthal, J. A., Chen, M. A., Cheng, S. C., Kitzman, D. W., Maurer, M. S., Rich, M. W., et al. (2013) · Circulation · doi:10.1161/01.cir.0000436752.99896.22 · Cited by 225
Bays, H. E., Gaudet, D., Weiss, R., Ruiz, J. L., Watts, G. F., Gouni‐Berthold, I., Robinson, J. G., Zhao, J. M., Hanotin, C., & Donahue, S. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1520 · Cited by 221
Garber, A. J., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., Dagogo-Jack, S. E., Davidson, M., EINHORN, D. F., Garvey, W. T., et al. (2013) · Endocrine Practice · doi:10.4158/ep13176.csuppl · Cited by 219
Should Diabetes Be Considered a Coronary Heart Disease Risk Equivalent?
Whiteley, L., Padmanabhan, S., Hole, D. J., & Isles, C. (2005) · Diabetes Care · doi:10.2337/diacare.28.7.1588 · Cited by 219
Wu, Y., Carballo‐Jane, E., McLaren, D. G., Mendoza, V., Gagen, K., Geoghagen, N. S. M., McNamara, L. A., Gorski, J. N., Eiermann, G. J., Petrov, A., et al. (2011) · Journal of Lipid Research · doi:10.1194/jlr.m019927 · Cited by 229
New Advances in Metabolic Syndrome, from Prevention to Treatment: The Role of Diet and Food
Ambroselli, D., Masciulli, F., Romano, E., Catanzaro, G., Besharat, Z. M., Massari, M. C., Ferretti, E., Migliaccio, S., Izzo, L., Ritieni, A., et al. (2023) · Nutrients · doi:10.3390/nu15030640 · Cited by 230
Response to Newly Prescribed Lipid-Lowering Therapy in Patients With and Without HIV Infection
Silverberg, M. J., Leyden, W., Hurley, L., Go, A. S., Quesenberry, C. P., Klein, D., & Horberg, M. A. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-5-200903030-00006 · Cited by 218
Vaughan, C. J., & Gotto, A. M. (2004) · Circulation · doi:10.1161/01.cir.0000139312.10076.ba · Cited by 220
Schwingshackl, L., & Hoffmann, G. (2013) · Journal of the Academy of Nutrition and Dietetics · doi:10.1016/j.jand.2013.07.010 · Cited by 218
Physician gender is associated with the quality of type 2 diabetes care
Berthold, H. K., Gouni‐Berthold, I., Bestehorn, K. P., Böhm, M., & Krone, W. (2008) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2008.01967.x · Cited by 225
Statin myopathy: A common dilemma not reflected in clinical trials
Fernandez, G., Spatz, E. S., Jablecki, C. K., & Phillips, P. S. (2011) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.78a.10073 · Cited by 217
Bipolar disorder and metabolic syndrome: An international perspective
McIntyre, R. S., Danilewitz, M., Liauw, S. S. L., Kemp, D. E., Nguyen, H. T., Kahn, L. S., Kucyi, A., Soczynska, J. K., Woldeyohannes, H. O., Lachowski, A. M., et al. (2010) · Journal of Affective Disorders · doi:10.1016/j.jad.2010.04.012 · Cited by 218
Lipoprotein(a) for Risk Assessment in Patients With Established Coronary Artery Disease
O’Donoghue, M. L., Morrow, D. A., Tsimikas, S., Sloan, S., Ren, A. F., Hoffman, E. B., Desai, N. R., Solomon, S. D., DOMANSKI, M. J., Arai, K., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.09.042 · Cited by 223
2018 Guidelines for the management of dyslipidemia
Rhee, E., Kim, H. C., Kim, J. H., Lee, E. Y., Kim, B. J., Kim, E. M., Song, Y., Lim, J. H., Kim, B. J., Choi, S., et al. (2019) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2019.188 · Cited by 221
Finken, M. J. J., van der Steen, M., Smeets, C. C. J., Walenkamp, M. J. E., de Bruin, C., Hokken-Koelega, A., & Wit, J. M. (2018) · Endocrine Reviews · doi:10.1210/er.2018-00083 · Cited by 232
Edison, R. J., & Muenke, M. (2004) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.30386 · Cited by 206
Friedewald, V. E., Kornman, K. S., Beck, J. D., Genco, R. J., Goldfine, A. B., Libby, P., Offenbacher, S., Ridker, P. M., Dyke, T. E. V., & Roberts, W. C. (2009) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2009.05.002 · Cited by 213
Metadata
- Authors
- Grundy, S. M., Cleeman, J. I., Merz, C. N. B., Brewer, H. B., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C., & Stone, N. J.
- Affiliations
- American College of Cardiology (US)
- Venue
- Circulation
- Published
- 2004-07-13
- Volume
- 110
- Issue
- 2
- Pages
- 227-239
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2106343349
- Cited by
- 6,902
- References
- 54
- Citations by year
- 2026: 32 · 2025: 44 · 2024: 72 · 2023: 71 · 2022: 85 · 2021: 100 · 2020: 127 · 2019: 137 · 2018: 152 · 2017: 189 · 2016: 248 · 2015: 324 · 2014: 382 · 2013: 506 · 2012: 489
- FWCI
- 539.21
- Type
- journal article
- Language
- en
- Update notices
- correction (2004-08-10)
- Open access
- bronze
- doi.org
- Locations
- Circulation (publishedVersion)
- PubMed (publishedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- UNC Libraries
- Funders
- American Heart Association
- American College of Cardiology Foundation
- National Heart, Lung, and Blood Institute
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Keywords
- Adult Treatment Panel III, LDL cholesterol targets, statin therapy, cholesterol-lowering therapy, diabetes mellitus, older adults, triglycerides, HDL cholesterol, nicotinic acid, therapeutic lifestyle changes, cardiovascular risk stratification, hypercholesterolemia, metabolic syndrome, cardiovascular disease prevention
- MeSH terms
- Aged, Anticholesteremic Agents, Antihypertensive Agents, Hypolipidemic Agents, Cardiovascular Diseases, Clinical Trials as Topic, Diabetes Mellitus, Humans, Hypercholesterolemia, Hypertension, Cholesterol, LDL, Middle Aged, Myocardial Infarction, Patient Education as Topic, Risk, Risk Factors, Comorbidity, Thrombolytic Therapy, Randomized Controlled Trials as Topic, Practice Guidelines as Topic, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Evidence-Based Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
